Outgoing Valeant CEO to testify at drug pricing hearing

The Senate Aging Committee announced that outgoing Valeant Pharmaceuticals CEO Michael Pearson has received a subpoena and is expected to testify at an April 27 hearing on increasing medication costs.

Valeant announced on March 21 that Pearson would leave the company but to continue to serve as CEO and a director until the company hires his replacement.

Valeant has received criticism since last year for increasing the prices of medications it bought. For instance, the Wall Street Journal reported last April that Valeant purchased the rights to two heart drugs (Nitropress and Isuprel) and increased their list prices by 525 percent and 212 percent, respectively.

Valeant announced last week that it had wrongly booked $58 billion in revenue. The company also recently launched a website with rebuttals to allegations against the company.

The Senate Aging Committee also held hearings in December 2015 and in March 2016. The committee said in a news release that Americans would spend more than $328 billion on prescription medications this year, while the federal government will spend another $110 billion in payments through Medicare, Medicaid, Veteran Affairs and other programs.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup